BR112022016167A2 - Composições e métodos para tratar e prevenir condições associadas à pré-calicreína - Google Patents
Composições e métodos para tratar e prevenir condições associadas à pré-calicreínaInfo
- Publication number
- BR112022016167A2 BR112022016167A2 BR112022016167A BR112022016167A BR112022016167A2 BR 112022016167 A2 BR112022016167 A2 BR 112022016167A2 BR 112022016167 A BR112022016167 A BR 112022016167A BR 112022016167 A BR112022016167 A BR 112022016167A BR 112022016167 A2 BR112022016167 A2 BR 112022016167A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- prekalkrein
- treat
- compositions
- conditions associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989427P | 2020-03-13 | 2020-03-13 | |
| PCT/US2021/022069 WO2021183857A1 (en) | 2020-03-13 | 2021-03-12 | Compositions and methods for treating and preventing prekallikrein-associated conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016167A2 true BR112022016167A2 (pt) | 2022-10-04 |
Family
ID=77672313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016167A BR112022016167A2 (pt) | 2020-03-13 | 2021-03-12 | Composições e métodos para tratar e prevenir condições associadas à pré-calicreína |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230149438A1 (enExample) |
| EP (1) | EP4118208A4 (enExample) |
| JP (2) | JP7795467B2 (enExample) |
| KR (1) | KR20220152569A (enExample) |
| CN (1) | CN115244179A (enExample) |
| AU (2) | AU2021233914B2 (enExample) |
| BR (1) | BR112022016167A2 (enExample) |
| IL (1) | IL295631B1 (enExample) |
| MX (1) | MX2022011205A (enExample) |
| WO (1) | WO2021183857A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9670492B2 (en) | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9670492B2 (en) * | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| ES2982752T3 (es) * | 2015-10-22 | 2024-10-17 | Iltoo Pharma | Composiciones farmacéuticas de il-2 |
| LT4119569T (lt) * | 2015-11-06 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| WO2018148449A1 (en) * | 2017-02-08 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Modulation of kallikrein b1 (klkb1) for treatment of headache |
-
2021
- 2021-03-12 US US17/908,773 patent/US20230149438A1/en active Pending
- 2021-03-12 AU AU2021233914A patent/AU2021233914B2/en active Active
- 2021-03-12 KR KR1020227035309A patent/KR20220152569A/ko active Pending
- 2021-03-12 IL IL295631A patent/IL295631B1/en unknown
- 2021-03-12 BR BR112022016167A patent/BR112022016167A2/pt unknown
- 2021-03-12 EP EP21768905.8A patent/EP4118208A4/en active Pending
- 2021-03-12 WO PCT/US2021/022069 patent/WO2021183857A1/en not_active Ceased
- 2021-03-12 JP JP2022552307A patent/JP7795467B2/ja active Active
- 2021-03-12 CN CN202180020558.4A patent/CN115244179A/zh active Pending
- 2021-03-12 MX MX2022011205A patent/MX2022011205A/es unknown
-
2025
- 2025-07-16 US US19/271,374 patent/US20260158051A1/en active Pending
- 2025-12-19 JP JP2025266910A patent/JP2026048915A/ja active Pending
-
2026
- 2026-05-13 AU AU2026203664A patent/AU2026203664A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295631B1 (en) | 2026-08-01 |
| AU2026203664A1 (en) | 2026-05-28 |
| WO2021183857A1 (en) | 2021-09-16 |
| EP4118208A1 (en) | 2023-01-18 |
| AU2021233914A1 (en) | 2022-09-08 |
| JP2026048915A (ja) | 2026-03-17 |
| MX2022011205A (es) | 2022-09-19 |
| US20230149438A1 (en) | 2023-05-18 |
| IL295631A (en) | 2022-10-01 |
| JP7795467B2 (ja) | 2026-01-07 |
| AU2021233914B2 (en) | 2026-04-30 |
| US20260158051A1 (en) | 2026-06-11 |
| EP4118208A4 (en) | 2025-03-12 |
| KR20220152569A (ko) | 2022-11-16 |
| JP2023519501A (ja) | 2023-05-11 |
| CN115244179A (zh) | 2022-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
| BR112021024055A2 (pt) | Composições e métodos para a regulação seletiva de gene | |
| BRPI0410731A (pt) | composto, composição farmacêutica, métodos para agonizar o receptor mc4, para tratar obesidade, para tratar diabetes melito e para tratar disfunção sexual masculina e/ou feminina em um mamìfero, e, uso de um composto | |
| BRPI0517135A (pt) | composições e métodos para tratar doenças neoplásticas | |
| DK1543011T3 (da) | Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander | |
| BR0314059A (pt) | Compostos heterocìclicos | |
| GT200000198A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos. | |
| BRPI0510274A (pt) | epìtopos relacionados à doença celìaca | |
| PH12023552830A1 (en) | Compositions and methods for inhibiting ketohexokinase | |
| CR20120415A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| EA200800337A1 (ru) | Композиция и способ введения офтальмологически активных средств | |
| CL2024003285A1 (es) | Anticuerpos bispecíficos y métodos de tratamiento de enfermedades oculares | |
| BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
| MX2024003529A (es) | Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica. | |
| CO2024012622A2 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| CL2025001956A1 (es) | Proteínas de unión al antígeno complemento c3 | |
| Yoodee et al. | Large-scale identification of calcium oxalate stone inhibitory proteins in normal human urine | |
| BR112022018945A2 (pt) | Tecnologias para prevenir ou tratar infecções | |
| DOP2024000180A (es) | Agentes de interferencia de arn de sarm1 | |
| Frallonardo et al. | Pain and microcrystalline arthritis | |
| MX2022011205A (es) | Composiciones y metodos para el tratamiento y la prevencion de afecciones asociadas a la precalicreina. | |
| WO2022256631A3 (en) | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| BR112022020342A2 (pt) | Inibidores da quinase | |
| BRPI0515893B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica. |